Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum SS18-5
- Development stage
- Preclinical
- Lead developer
- Beijing Fulerton BioEngineering
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum SS18-5 is a probiotic bacterial strain developed through space-induced mutagenesis, resulting in unique properties compared to conventional strains. This strain has demonstrated significant hypoglycemic effects in animal models of type 2 diabetes mellitus (T2DM), including lowering fasting blood glucose, glycosylated hemoglobin, and insulin levels; increasing liver glycogen; improving lipid metabolism; reducing oxidative stress and chronic inflammation; alleviating fatty liver disease; and modulating the intestinal microbiota by decreasing harmful bacteria (Escherichia coli, Clostridium perfringens) while increasing beneficial lactobacilli. The mechanism of action involves regulation of host metabolism and immune modulation via changes in gut microbiota composition and reduction of inflammatory markers[1][3]. It is being investigated primarily as a live biotherapeutic product for metabolic disorders such as T2DM.
- Other names
- L. plantarum SS18-5space-induced Lactobacillus plantarum SS18-5
Beyond the preview
Go deeper on Lactobacillus plantarum SS18-5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum SS18-5.